Eli Lilly to invest $3 billion in China, seeks approval for new GLP-1 drug

Investing.com Gold reports: Eli Lilly to invest $3 billion in China, seeks approval for new GLP-1 drug. This is a premium/paywalled source, so the brief is based on headline and available metadata only.